Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology

Journal of Virology

Volumn 89, Issue 6, 2015, Pages 2995-3007

  Honda Okubo, Yoshikazu ^a   Barnard, Dale ^b   Ong, Chun Hao ^a   Peng, Bi Hung ^c   Tseng, Chien Te Kent ^c   Petrovsky, Nikolai ^a,d  

^a VAXINE PTY LTD   (Australia)

^b UTAH STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; DELTA INULIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 14; INTERLEUKIN 2; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; ADVAX; CORONAVIRUS SPIKE GLYCOPROTEIN; INULIN; VIRUS VACCINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; INFECTION PREVENTION; LOEFFLER PNEUMONIA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEVERE ACUTE RESPIRATORY SYNDROME; TH1 TH2 BALANCE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; EOSINOPHIL; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; LUNG; PATHOLOGY; SARS CORONAVIRUS; TH1 CELL; VIROLOGY;

CORONAVIRUS; MURINAE; MUS; SARS CORONAVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; EOSINOPHILS; FEMALE; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-4; INULIN; LUNG; MICE; MICE, INBRED BALB C; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPIKE GLYCOPROTEIN, CORONAVIRUS; TH1 CELLS; VIRAL VACCINES;

EID: 84923169092     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02980-14     Document Type: Article

References (53)

1. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967-1976. http://dx.doi.org/10.1056/NEJMoa030747.
2. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399. http://dx.doi.org/10.1126/science.1085952.
3. Nicholls J, Dong XP, Jiang G, Peiris M. 2003. SARS: clinical virology and pathogenesis. Respirology 8(Suppl):S6-S8. http://dx.doi.org/10.1046/j .1440-1843.2003.00517.x.
4. Graham RL, Donaldson EF, Baric RS. 2013. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11:836-848. http://dx.doi.org/10.1038/nrmicro3143.
5. Callow KA, Parry HF, Sergeant M, Tyrrell DA. 1990. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect 105:435-446. http://dx.doi.org/10.1017/S09502688000480 19.
6. Tang F, Quan Y, Xin ZT, Wrammert J, Ma MJ, Lv H, Wang TB, Yang H, Richardus JH, Liu W, Cao WC. 2011. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol 186:7264-7268. http://dx .doi.org/10.4049/jimmunol.0903490.
7. Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, Chen KH, Liu FT, Liu WT, Chen YM, Huang JC. 2014. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 451:208-214. http://dx.doi.org/10.1016/j.bbrc.2014.07.090.
8. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA. 2013. Hospital outbreak of Middle East respiratory syndrome coronavirus.NEngl JMed369:407-416. http://dx.doi.org/10.1056/NEJMoa1306742.
9. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, et al. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399-1404. http://dx.doi.org/10.1126/science .1085953.
10. Darnell ME, Plant EP, Watanabe H, Byrum R, St Claire M, Ward JM, Taylor DR. 2007. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J Infect Dis 196:1329-1338. http://dx.doi.org/10 .1086/522431.
11. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. 2011. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 85:12201-12215. http://dx.doi.org/10.1128/JVI.06048-11.
12. See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB. 2006. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87:641-650. http://dx.doi.org/10 .1099/vir.0.81579-0.
13. Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, Kase R, Sekiguchi S, Morita K, Hishima T, Suzuki H, Karamatsu K, Yasutomi Y, Shida H, Kidokoro M, Mizuno K, Matsushima K, Kohara M. 2008. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 181:6337-6348. http://dx.doi.org/10.4049/jimmunol.181.9.6337.
14. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. 2012. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7:e35421. http://dx.doi.org/10.1371/journal .pone.0035421.
15. Clay C, Donart N, Fomukong N, Knight JB, Lei W, Price L, Hahn F, Van Westrienen J, Harrod KS. 2012. Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. J Virol 86:4234-4244. http://dx.doi .org/10.1128/JVI.06791-11.
16. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454. http://dx.doi.org/10 .1038/nature02145.
17. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, Thomas WD, Jr, Thackray LB, Young MD, Mason RJ, Ambrosino DM, Wentworth DE, Demartini JC, Holmes KV. 2004. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 101:15748-15753. http://dx.doi .org/10.1073/pnas.0403812101.
18. Huang J, Cao Y, Du J, Bu X, Ma R, Wu C. 2007. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 25:6981-6991. http://dx.doi.org/10.1016/j.vaccine.2007.06.047.
19. Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M, Cox M. 2006. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24:3624-3631. http://dx.doi.org/10.1016/j .vaccine.2006.01.059.
20. Openshaw PJ, Culley FJ, Olszewska W. 2001. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20(Suppl 1):S27-S31. http://dx .doi.org/10.1016/S0264-410X(01)00301-2.
21. Petrovsky N, Aguilar JC. 2004. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82:488-496. http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x.
22. Petrovsky N, Cooper PD. 2011. Carbohydrate-based immune adjuvants. Expert Rev Vaccines 10:523-537. http://dx.doi.org/10.1586/erv.11.30.
23. Cooper PD, Petrovsky N. 2011. Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2→1]poly(fructofuranosyl) alpha-D-glucose polymers. Glycobiology 21:595-606. http://dx .doi.org/10.1093/glycob/cwq201.
24. Layton RC, Petrovsky N, Gigliotti AP, Pollock Z, Knight J, Donart N, Pyles J, Harrod KS, Gao P, Koster F. 2011. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 29:6242-6251. http://dx.doi .org/10.1016/j.vaccine.2011.06.078.
25. Honda-Okubo Y, Saade F, Petrovsky N. 2012. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 30:5373-5381. http://dx.doi.org/10.1016/j.vaccine.2012 .06.021.
26. Larena M, Prow NA, Hall RA, Petrovsky N, Lobigs M. 2013. JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8+ T cells and preexposure neutralizing antibody. J Virol 87:4395-4402. http://dx.doi.org/10.1128/JVI.03144-12.
27. Petrovsky N, Larena M, Siddharthan V, Prow NA, Hall RA, Lobigs M, Morrey J. 2013. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol 87:10324-10333. http://dx.doi.org/10.1128/JVI.00480-13.
28. Saade F, Honda-Okubo Y, Trec S, Petrovsky N. 2013. A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 31:1999-2007. http://dx.doi .org/10.1016/j.vaccine.2012.12.077.
29. Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R. 2011. Induction of mucosal and systemic antibody and T-cell responses following primeboost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 92:128-140. http://dx.doi.org/10.1099/vir.0.023242-0.
30. Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, Petrovsky N. 2012. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 30:5407-5416. http://dx.doi.org/10.1016/j.vaccine.2012.06.009.
31. Gordon D, Kelley P, Heinzel S, Cooper P, Petrovsky N. 27 September 2014. Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled phase 1 study. Vaccine http://dx.doi.org/10.1016/j.vaccine.2014.09.034.
32. Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL. 2009. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 395: 210-222. http://dx.doi.org/10.1016/j.virol.2009.09.023.
33. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623-1631. http://dx.doi.org/10.1084/jem.186 .10.1623.
34. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CT, Li F, Zhou Y, Jiang S, Du L. 2014. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design. Vaccine 32:6170-6176. http://dx.doi.org/10.1016/j.vaccine.2014.08.086.
35. Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF. 2005. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol 175:5895-5903. http://dx.doi.org/10.4049/jimmunol.175.9.5895.
36. Geginat J, Lanzavecchia A, Sallusto F. 2003. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101:4260-4266. http://dx.doi .org/10.1182/blood-2002-11-3577.
37. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712. http://dx.doi.org/10.1038/44385.
38. Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, Das D, Sun LQ, Wang M, Salazar AM. 2009. Activation of Toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27:3481-3483. http://dx.doi.org/10.1016/j.vaccine.2009.01.048.
39. Berger A, Drosten C, Doerr HW, Sturmer M, Preiser W. 2004. Severe acute respiratory syndrome (SARS)-paradigm of an emerging viral infection. J Clin Virol 29:13-22. http://dx.doi.org/10.1016/j.jcv.2003.09.011.
40. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. 2014. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol 88:11034-11044. http://dx.doi.org/10.1128/JVI.01505-14.
41. Terhune TD, Deth RC. 2013. How aluminum adjuvants could promote and enhance non-target IgE synthesis in a genetically-vulnerable subpopulation. J Immunotoxicol 10:210-222. http://dx.doi.org/10.3109/1547691X.2012.708366.
42. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. 1998. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A 95:15553-15558. http://dx.doi.org/10.1073/pnas.95 .26.15553.
43. Zhao J, Lloyd CM, Noble A. 2013. Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling. Mucosal Immunol 6:335-346. http://dx .doi.org/10.1038/mi.2012.76.
44. Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S. 2013. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J Virol 87:6551-6559. http://dx.doi.org/10.1128/JVI.00087-13.
45. Nieto-Torres JL, DeDiego ML, Verdia-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA, Fernandez-Delgado R, Castano-Rodriguez C, Alcaraz A, Torres J, Aguilella VM, Enjuanes L. 2014. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog 10:e1004077. http://dx .doi.org/10.1371/journal.ppat.1004077.
46. Smits SL, van den Brand JM, de Lang A, Leijten LM, van Ijcken WF, van Amerongen G, Osterhaus AD, Andeweg AC, Haagmans BL. 2011. Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. J Virol 85:4234-4245. http://dx.doi.org/10.1128/JVI.02395-10.
47. Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman M, Dyer MD, Teal TH, Proll S, van den Brand J, Baric R, Katze MG. 2009. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 83:7062-7074. http://dx.doi.org/10.1128/JVI.00127-09.
48. Page C, Goicochea L, Matthews K, Zhang Y, Klover P, Holtzman MJ, Hennighausen L, Frieman M. 2012. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J Virol 86:13334-13349. http://dx.doi.org/10.1128/JVI.01689-12.
49. DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guardeno JM, Fernandez-Delgado R, Fett C, Castano-Rodriguez C, Perlman S, Enjuanes L. 2014. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol 88:913-924. http://dx.doi.org/10.1128/JVI.02576-13.
50. Zhao J, Wohlford-Lenane C, Zhao J, Fleming E, Lane TE, McCray PB, Jr, Perlman S. 2012. Intranasal treatment with poly(I*C) protects aged mice from lethal respiratory virus infections. J Virol 86:11416-11424. http://dx.doi.org/10.1128/JVI.01410-12.
51. Kong SL, Chui P, Lim B, Salto-Tellez M. 2009. Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. Virus Res 145:260-269. http://dx.doi.org/10.1016/j.virusres.2009.07.014.
52. Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. 2009. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol 83:3039-3048. http://dx.doi.org/10.1128/JVI.01792-08.
53. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. 2014. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol 88:8597-8614. http://dx .doi.org/10.1128/JVI.00983-14.